Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
Singanayagam, Aran; Aliberti, Stefano; Cillóniz, Catia; Torres, Antoni; Blasi, Francesco; Chalmers, James D.

Published in: European Respiratory Journal

DOI: 10.1183/13993003.02306-2016

Publication date: 2017

Document Version
Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
SUPPLEMENTARY METHODS

INCLUSION/EXCLUSION CRITERIA FOR INDIVIDUAL COHORTS

Milan cohort

Inclusion criteria:
Pneumonia was defined as the presence of a new pulmonary infiltrate on chest radiograph at the time of hospitalization associated with 1 of the following: (1) new or increased cough with/without sputum production; (2) fever (>37.8°C) or hypothermia (<35.6°C); or (3) abnormal white blood cell count (either leukocytosis or leukopenia), or C-reactive protein values above the local upper limit.

Exclusion criteria:
Hospitalisation within 15 days prior to admission

FAILCAP cohort

Inclusion criteria:
1. New pulmonary infiltrate seen on chest radiograph or CT Scan of the chest within 48 hours after hospitalization. (The finding of infiltrate by chest radiograph or other imaging technique is "required" for the diagnosis of pneumonia, according to the 2007 consensus guidelines from the Infectious Diseases Society of America and the American Thoracic Society (2). Patients identified during the screening process will be enrolled if a chest radiograph or CT Scan of the chest taken within 48 hours after hospital admission revealed a new infiltrate consistent with pneumonia

plus at least one of the following:

2. New or increased cough with/without sputum production
3. Fever (documented temperature -rectal or oral- >37.8°C) or hypothermia (documented temperature –rectal or oral- <35.6°C)
4. Abnormal white blood cell count, either leukocytosis (>10,000/cm³) or leucopenia (< 4,000/cm³)

This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.
**Exclusion criteria:**

Patients who meet at least one of the following definitions will be excluded from the analysis:

1) Patient has hospital-acquired pneumonia, defined as pneumonia that develops after 48 hours of the current hospitalization, or pneumonia that develops in a patient who had been discharged from the hospital within the prior 14 days of the current hospitalization.

2) Patient is re-admitted with a new episode of pneumonia during the 30-day follow up period.

3) Unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete the study requirements.

4) Subject history that in the investigator’s opinion would preclude subject compliance with the protocol.

**Edinburgh cohort**

**Inclusion criteria:**

Patients were included in the study if they presented with a new infiltrate on chest radiograph and had 3 or more of the following symptoms or signs (cough, sputum production, breathlessness, pleuritic chest pain or signs consistent with pneumonia on auscultation).

**Exclusion criteria:**

Hospital-acquired pneumonia (development of symptoms >48 hours following admission or discharge from an acute care facility <2 weeks prior to admission); active thoracic malignancy; immunosuppression (defined as current (>28 day) use of oral prednisolone at any dose or other immunosuppressive drugs (methotrexate, azathioprine, cyclosporin and anti-tumour necrosis factor alpha agents) or patients
with solid organ transplantation); pulmonary embolism and patients in whom active
treatment was not considered appropriate (palliative care).

**Barcelona cohort**

**Inclusion criteria:**
Adult patients (>18 years) presenting with pneumonia, defined as the presence of a
new infiltrate on a chest radiograph together with clinical symptoms that were
suggestive of lower respiratory tract infection (e.g. fever, cough, sputum production,
pleuritic chest pain).

**Exclusion criteria:**
1) patients without a positive microbiologic diagnosis, 2) severe immunosuppression
(AIDS, chemotherapy, immunosuppressive drugs [e.g., oral corticosteroid ≥10 mg
prednisone or equivalent per day for at least two weeks]), 3) health care-associated
pneumonia cases, 4) active tuberculosis, 5) patients with cystic fibrosis, and 6) cases
with a confirmed alternate diagnosis

**Microbiological testing for atypical pathogens**

**Milan and FAILCAP cohorts:**

**PCR based identification**
Nested PCR with primers amplifying 207-bp fragment of major outer member
protein genes (ompA) of *Chlamydia pneumoniae*, 104-bp fragment P1 protein
antigen of *Mycoplasma pneumoniae* and 403-bp fragment of the macrophage
infectivity potentiator protein (MIP) of *Legionella pneumophila* were used. After
amplification, 4% agarose gel electrophoresis and sybr safe DNA stain were used to
visualise the PCR products.

**Serology:**

*Chlamydia pneumoniae*: the presence of serum antibodies (IgG, IgA, IgM) was
determined by the ANI Labsystems microimmunofluorescence (MIF) test. The serum
samples were considered positive when there were titers of >1:64 for IgG antibodies and >1:16 for IgA and IgM.

*Mycoplasma pneumoniae*: the detection of serum antibodies (IgG, IgM) was determined by an enzyme-linked immunosorbent assay (ELISA) (Viro-Immun Labor – Diagnostika GmbH).

**Edinburgh cohort:**

Testing for atypical pathogens (urine testing for Legionella and PCR based testing for *M. pneumoniae* and *C. pneumoniae*) was conducted in accordance with the British Thoracic Society/NICE guidelines, as previously reported⁹.

**Barcelona cohort:**

Blood samples for serology of atypical pathogens were performed at admission and within the third and sixth week thereafter. The etiology was considered definite if the following criteria was met: 1) elevated serum levels of IgM against *C. pneumoniae* (≥1:64), *C. burnetii* (≥1:80) and *M. pneumoniae* (any positive titre) 2) seroconversion (ie, a fourfold increase in IgG titres) for *C. pneumoniae* and *L. pneumophila* >1:128, *C. burnetii* >1:80